CD4+T Cell Count Recovery in HIV Type 1–Infected Patients Is Independent of Class of Antiretroviral Therapy | Zendy

Nina Khanna | Zendy; Milos Opravil | Zendy; Hansjakob Furrer | Zendy; Matthias Cavassini | Zendy; Pietro Vernazza | Zendy; Enos Bernasconi | Zendy; Rainer Weber | Zendy; Hans H. Hirsch | Zendy; Manuel Battegay | Zendy; Gilbert R. Kaufmann | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CD4⁺T Cell Count Recovery in HIV Type 1–Infected Patients Is Independent of Class of Antiretroviral Therapy

Author(s) -

Nina Khanna,

Milos Opravil,

Hansjakob Furrer,

Matthias Cavassini,

Pietro Vernazza,

Enos Bernasconi,

Rainer Weber,

Hans H. Hirsch,

Manuel Battegay,

Gilbert R. Kaufmann

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/592113

Subject(s) - medicine , virology , reverse transcriptase , protease inhibitor (pharmacology) , antiretroviral therapy , human immunodeficiency virus (hiv) , reverse transcriptase inhibitor , lentivirus , protease , sida , immunology , viral disease , viral load , polymerase chain reaction , biology , enzyme , biochemistry , gene

In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infection have changed from nonboosted protease inhibitors (PIs) to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and boosted PI-based antiretroviral drug regimens, but the impact on immunological recovery remains uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research